Sweden
· Delayed Price · Currency is SEK Abliva AB Company Description
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden.
The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications.
It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children’s Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments.
The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020.
Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
| Country | Sweden |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Ellen Donnelly |
Contact Details
Address: Medicon Village Lund, 223 81 Sweden | |
| Phone | 46 4 62 75 62 20 |
| Website | abliva.com |
Stock Details
| Ticker Symbol | ABLI |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0002575340 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Catharina Jz Johansson | Deputy Chief Executive Officer, Chief Financial Officer and Vice President of Investor Relations |
| Dr. Ellen K. Donnelly Ph.D. | Chief Executive Officer |
| Dr. Eskil Elmér M.D., Ph.D. | Chief Scientific Officer and Vice President of Discovery |
| Eleonor Åsander Frostner | Communications Officer and Lab Manager |
| Dr. Magnus Hansson | Chief Medical Officer and Vice President of Preclinical and Clinical Development |
| Dag Nesse | Vice President of Clinical Operations |
| Dr. Lars Vedin | Consultant |